Actividad Investigadora
Early detection of respiratory disorders in psychosis
Datos básicos
- Código del Financiador:
- PRIMVAL17/06
- Año Inicial:
- 2017
- Año final:
- 2021
Objetivos del proyecto
Asthma and COPD are chronic respiratory disorders with high prevalence in the general population. Tobacco smoking is the leading risk factor for COPD, and has been associated with higher risk for uncontrolled asthma. Tobacco smoking is widely extended in the general population and is highly associated with cannabis use, which is the most consumed illicit drug in Spain. Other described risk factors for poor lung function are metabolic alterations such as insulin resistance and diabetes, and even abdominal obesity. Patients with psychosis present remarkably higher prevalence of tobacco and cannabis consumption than the general population and higher risk for developing metabolic alterations such as obesity and diabetes at the long-run. Despite these premises, the effect of metabolic alterations and tobacco and cannabis smoking on the respiratory health has been poorly studied. Previous studies, mainly based on patients’ registers showed an increased risk for COPD and uncontrolled asthma in patients with psychosis. Few studies have analysed this relation using lung function tests (spirometry), reporting reduced spirometry values (FVC and FEV1) in patients with schizophrenia compared with healthy controls. But little data is available on the possible causative relation of smoking (tobacco and cannabis) and metabolic alterations of COPD and un-controlled asthma in psychosis. Based on the available scientific evidence, we hypothesize that patients with psychosis will present differences in prevalence and severity of lung disease and poorer lung function, compared with the general (non-psychiatric) population, probably related to smoking (tobacco and cannabis) and metabolic alterations. Therefore, the main objective would be to evaluate the presence of lung function impairment in a sample of patients diagnosed with non-affective psychosis. Our research plan encompasses: Task 1. To study the patients sampling and clinical phenotyping; Patients with a non-affective psychosis, already enrolled in the long-term (10 years) longitudinal study (“PAFIP-10 study”), would be recruited for the present study. Patients´ information regarding weight gain, metabolic parameters, tobacco and cannabis consumption would be collected. Quality of life, functioning, disability, physical activity would be evaluated through scales (QLS, GAF, DAS, and MERV); Task 2. To carry out lung function tests with spirometry, in those patients with schizophrenia after 10 years of initiated their psychotic illness, therefore with a mean age of 38 years-old. Respiratory symptomatology would be evaluated through clinical scales (CAT, mMRC, and ACT). We propose an innovative project to study cross-sectionally the respiratory health of patients suffering from schizophrenia. This project takes advantage of an exceptional longitudinal cohort of patients with schizophrenia, and a collaborative approach between three research and clinical groups in respiratory disease (ACINAR and HUMV Respiratory Department) and psychosis (Psychiatry-IDIVAL group) areas. The experience and the expertise of the applicant groups with influential publications, the availability of the necessary infrastructure, and the availability of samples, ensure the viability of the project.
Documentos
- No hay documentos
